





European Brain Council, Rice University Baker Institute for Public Policy, and Brain Capital Alliance

With support from Roche

Brain Health for Society: Insights from Brain Capital

Date: January 25th, 2024

Duration: 10.00 – 17.15 (Registration & Networking Coffee begins at 9:15)

Location: Hyperion Hotel - Messeplatz 12, 4058 Basel, Switzerland

Background

On 25 January 2024, following the World Economic Forum in Davos, the European Brain Council, in partnership with Rice University Baker Institute for Public Policy and the Brain Capital Alliance will host a full day event, Brain Health for Society: Insights from Brain Capital, in Basel, Switzerland.

Brain disorders – encompassing neurological diseases and disorders and mental illnesses – are widespread, disabling and difficult to treat. These include a range of conditions: epilepsy, depression, Alzheimer's disease, Multiple Sclerosis, Parkinson's, depression, stroke, Schizophrenia, headache, anxiety disorders, chronic pain and rarer brain disorders such as amyotrophic lateral sclerosis (ALS), dystonia and ataxia. In fact, it is estimated that up to one billion people worldwide live with a neurological condition and 970 million people around the world were living with a mental health disorder as of 2019, with anxiety and depressive disorders the most common.

These numbers are alarming without considering that they pre-date the COVID-19 pandemic, which we now know led to higher rates of mental health conditions as well as COVID-19-triggered neurological complications. These conditions represent a high individual, social and economic burden and contribute to the global disease burden and disability.

This conference will showcase the importance and urgency of prioritising brain health, particularly by presenting the novel concept of 'Brain Capital', which puts a premium on cognitive skills and abilities in accomplishing socio-economic objectives. Building Brain Capital is fundamental for meeting modern societal challenges, driving innovation and achieving economic security. Policies and investments to boost brain power can increase productivity, stimulate greater creativity and economic dynamism, afford social cohesion, and create a more resilient, adaptable, and sustainability-engaged populace. This discussion is incredibly timely, particularly as we enter 2024, when many major elections are taking place e.g., European elections, the Presidency of the United States of America, for the UK Prime Ministership, etc. and we are witnessing times of major political, economic, and overall societal shifts and instability. Coordinating brain health and brain capital advances across the Atlantic and globally is vital.

Agenda

9.15 – 10.00 Registration and Networking Coffee

10.00 – 10.02 Opening Remarks from Local Host

Jan Schadrack, Global Head Medical Affairs, Neuroscience and Rare Diseases, Roche

10.02 – 10.10 Welcome Remarks from Co-Convenor

Frédéric Destrebecq, Executive Director, European Brain Council

10.10 – 10.20 Brain Capital Provides Hope

Hon. Sir Norman Lamb MP, Chair, South London and Maudsley NHS Foundation Trust; former Minister responsible for Mental Health

10.20 – 10.30 Impacts of Brain Health on the Economy

William Heisel, Director of Global Services, Institute for Health Metrics and Evaluation

10.30 – 10.40 Brain Capital: Public-Private Perspectives

Harris Eyre, Lead, Brain Capital Alliance. Fellow, Rice University's Baker Institute for Public Policy. Senior Fellow, Meadows Mental Health Policy Institute, Lead, Brain Capital Alliance

10.40 – 10:50 European Brain Plans: The State of the Art

Claudio Bassetti, Vice President, European Brain Council; Lead, Swiss Brain Health Plan

10.50 – 11.20 Panel 1: Brain Health Clinical Innovation in Children and Youth

CHAIR and MODERATOR: Frédéric Destrebecq, Executive Director, European Brain Council

- Mikele Epperly, Global Integrated Program Leader, Brain Health & Neurology Healthcare Ecosystems, Roche
- Tim Foxx, Director, Center for School Study Councils, University of Pennsylvania
- Carmen Moreno, Chair, Child and Adolescent Neuropsychopharmacology Network, ECNP; Child and Adult Psychiatrist, Hospital Gregorio Marañón, Madrid, Spain
- Kevin Rostasy, President, European Paediatric Neurology Society (EPNS)

11.20 - 11.35 Guided Discussion

11.35 – 11.50 Networking Break

11.50 – 12.00 The State of Global Democracy

Alexander Hudson, Senior Adviser, Democracy Assessment Unit, International IDEA

12.00 – 12.10 Neuroscience and Sustainability

Dennis Pamlin, Executive Director, The Net-Zero Compatibility Initiative, Mission Innovation

12.10 – 12.50 Panel 2: Brain Health Clinical Innovation in Mid- and Late-Life

CHAIR and MODERATOR: Frédéric Destrebecg, Executive Director, European Brain Council

- Paulo Fontoura, Global Head and SVP Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Roche
- Maria Teresa Ferretti, Affiliated researcher, Center for Alzheimer Studies, Karolinska Institut; External teacher (Privat Dozent), Medical university of Vienna; Clinical Development Lead, Syntropic Medical
- Peter Falkai, Board Member, European Brain Council; Past President, European Psychiatric Association
- Quazi Haque, Chief Medical Officer, Elysium Healthcare & Global Mental Health & Brain Science CoP Lead, Ramsay Healthcare
- Craig Ritchie, CEO and Founder, Scottish Brain Sciences

12.50 – 13.00 The Patient Perspective

Orla Galvin, Executive Director, European Federation of Neurological Associations

13.00 - 14.00 Networking Lunch

14.00 – 14.10 Advances from Denmark on Public Private Partnerships and Brain Plans

Tina Hjortlund, Head of Global Public Affairs and DE&I Officer, Lundbeck

14.10 – 14.20 Economics needs brain capital

William Hynes, Adjunct Professor at Rebuilding Macroeconomic, University College London; Adjunct Professor, Santa Fe Institute; Adjunct Professor, Johns Hopkins School for Advanced International Studies; World Bank economist

14.20 – 15.00 Panel 3: Next Generation Brain Plans

CHAIR and MODERATOR: Paweł Świeboda, Founder, Neurocentury

- Marco Mohwinckel, mental health and health technology investor and advisor
- Marcel Tanner, President, Swiss Academies of Arts & Sciences
- Peter Falkai, Board Member, European Brain Council; Lead Author of the German Brain Plan
- Azad Bonni, SVP Roche pRED Global Head of Neuroscience & Rare Diseases, Roche
- Henrik Peersen, Secretary General, Hjernerådet (Norwegian Brain Council)

15.00 – 15.15 Networking break

15.15 – 15.25 Brain Health for Society: Scaling what works to add years to life and life to years

Kana Enomoto, Director of Brain Health, McKinsey Health Institute

15.25 – 16.05 Panel 4: Brain Capital and Impact Investing

CHAIR and MODERATOR: Rym Ayadi, Adjunct Professor of Banking, Finance and Economics, Bayes Business School at City University London; Founder and President of the Euro-Mediterranean Economists Association (EMEA)

- Shiva Dustdar, Head, European Investment Bank Institute
- Ekkehard Ernst, President, Geneva Macro Labs
- Nathalie Hilmi, Head of Environmental Economics, Center for Science, Monaco
- Alex Struc, CEO, Goalsfirst

16.05 – 16.15 Toward a Brain Health Industrial Innovation Strategy

George Vradenburg, Chairman, Davos Alzheimer's Collaborative

16.15 – 16.45 Panel 5: Pathways Forward for Brain Capital

CHAIR and MODERATOR: Paweł Świeboda, Founder, Neurocentury

- Shiva Dustdar, Head of the European Investment Bank Institute
- Michael Oberreiter, Head of Global Access, Roche
- Harris Eyre, Lead, Brain Capital Alliance; Fellow, Rice University's Baker Institute for Public Policy; Senior Fellow, Meadows Mental Health Policy Institute, Lead, Brain Capital Alliance

16.45 – 17.10 Audience Discussion

17.10 – 17.15 Concluding Remarks

Frédéric Destrebecq, Executive Director, European Brain Council

Key resources:

Ayadi, Eyre et al (2023) Global Brain Capital Dashboard. The Brookings Institution https://www.brookings.edu/articles/the-global-brain-capital-dashboard/

Eyre, Ayadi, Meidl, Swieboda, Destrebecq et al. "Brain Capital is Key to a Sustainable Future." Research paper no. 07.10.23. Rice University's Baker Institute for Public Policy, Houston, Texas. https://doi.org/10.25613/5yez-tc65.

Eyre, Ayadi, Meidl, Swieboda, Destrebecq et al. 2023. 7 Steps for Igniting the Brain Capital Industrial Strategy. Research paper no. 09.14.23. Rice University's Baker Institute for Public Policy, Houston, Texas. https://doi.org/10.25613/TYZC-0N60.

EMEA. 2022. At COP 27, Brain Capital emerges as a new vector for sustainability. https://euromed-economists.org/at-cop-27-brain-capital-emerges-as-a-new-vector-for-sustainability/

Lancet Neurology (2023) Sustainable development demands brain health. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00337-X/fulltext



Jan Schadrack

Global Head Medical Affairs, Neuroscience and Rare Diseases, Roche

Jan has worked with Roche since 2015 and serves as the Global Head Neuroscience and Rare Diseases for Medical Affairs. Jan is passionate about Medicine and Neuroscience and strongly believes that the possibilities of the biosciences and the digital age are rapidly transforming the science and medical practice especially of nervous system disorders and are paving the way for the 'neurology revolution' and 'brain health'. He is strongly inspired by how this will bring better solutions and wellbeing for patient care, the medical community, healthcare ecosystems, and ultimately society as a whole.

Jan is an MD PhD and specialized in psychiatry and neuropharmacology (in Munich, Max-Planck Institute of Clinical Psychiatry). In the biopharmaceutical industry he held various Clinical Development and Medical Affairs roles and gained longstanding and profound experience in Neuroscience including rare neurological diseases - having worked across many Neurology and Psychiatry disease areas with Novartis, Bristol-Myers Squibb, Johnson & Johnson, Biogen, before joining Roche.





Frédéric Destrebecq

Executive Director, European Brain Council

Frédéric Destrebecq is the Executive Director of the European Brain Council since October 2014. In this capacity, he is responsible for providing strategic direction and leadership while managing the day to day operations of EBC and its ongoing relationships with its member associations and other stakeholders, as well as representing the organisation in various European and national forums.

Fred holds a Master Degree in Political Science and International Relations from the Université Catholique de Louvain (Belgium). He also studied at the Institut d'Etudes Politiques (Paris) and University of Wales College (Cardiff), in the framework of the former EU Socrates exchange programme. Prior to EBC, Fred served the European Union of Medical Specialists (UEMS) as Chief Executive Officer, and previously as Director for European Affairs.





Sir Norman Lamb

Chair, South London and Maudsley NHS Foundation Trust; former Minister responsible for Mental Health

Sir Norman Lamb is currently Chair of South London and Maudsley NHS Foundation Trust. He is a former Member of Parliament for 18 years representing North Norfolk (2001 - 2019); Minister of State for Care and Support in Department of Health from 2012 - 2015; Chair, Science and Technology Parliamentary Select Committee from 2017 - 2019; and Hon Fellow, Royal College of Psychiatrists. Prior to election to Parliament, lawyer specialising in employment law.

Sir Norman Lamb was knighted in 2019 for his public and political service, notably with citation to his passionate work in the field of mental health.













William Heisel

Director of Global Services, Institute for Health Metrics and Evaluation

William Heisel is the Executive Director for IHME Client Services, leading a social enterprise to engage with the private sector to support innovation at the Institute for Health Metrics and Evaluation (IHME). IHME produces the world's largest independent health database with state-of-the-art research, analytic, and display tools and Bill oversees a team to help support private sector efforts by providing access to comprehensive data and analytics to improve health through data-driven solutions in policy and decision making.

IHME tracks all aspects of health, including matters of brain health—encompassing neurological, cerebrovascular, and mental health disorders globally. The Brain Health Initiative was established to provide effective evidence for decision-makers and communicate the urgency of brain disorders around the world. IHME Client Services is building a collaborative of likeminded organizations who share the goal of reducing the burden of brain disorders, prioritizing brain health globally and furthering the research to understand the present and future burden of brain health.

Previously, as the Director of Global Engagement at IHME, Bill oversaw the Institute's outreach and relationship building, including media relations, digital communications, data library services, events and marketing, publications, scientific communications, and external relations. He also managed philanthropic fundraising efforts and helped create the Roux Prize, one of global health's highest honors.





Harris Eyre

Lead, Brain Capital Alliance. Fellow, Rice University's Baker Institute for Public Policy. Senior Fellow, Meadows Mental Health Policy Institute, Lead, Brain Capital Alliance

Dr Eyre is an entrepreneur dedicated to creating awareness, knowledge, skills, and leadership for the brain economy. He works across public, nonprofit and private sectors, with the goal to achieve flourishing, economic and national security for communities. He is a senior fellow at Meadows Mental Health Policy Institute, as well as an advisor to the Euro-Mediterranean Economists Association and Kooth.

The leading force behind Brain Capital and the Brain Capital Alliance, major international policy organizations now emphasize that investing in the development of Brain Capital is indispensable for tackling contemporary societal challenges and fostering innovation. Brain Capital has been highlighted in platforms such as the UNGA, Bloomberg, COP, OECD, Forbes, Wharton, PwC, The FT, Brookings, The Lancet, and US Congress.

Eyre and his colleagues are advancing a global strategy, aimed at integrating Brain Capital considerations into all policy domains. Additionally, they are championing an investment plan, which has led to the formation of a new venture capital fund.

He is also lead in the Champion's Cabinet of the Davos Alzheimer's Collaborative, a fellow with the Stanford Frontier Technology Lab, an alumnus of the Forbes 30 Under 30 and the Fulbright Scholar program, as well as an awardee of the EB1A Green Card, an honor typically reserved for Nobel and Pulitzer prize winners. He has authored 200+ papers and was the lead editor of the book 'Convergence Mental Health' (Oxford Press).













Claudio L. A. Bassetti

Vice President, European Brain Council; Lead, Swiss Brain Health Plan

Claudio Lino Alberto Bassetti is Full Professor and Chair, Neurology Department Inselspital, University Hospital, Bern, Switzerland. Born and raised in Ticino, is married and father of three boys. He speaks six languages and enjoys music, history, and sports.

Bassetti received his MD degree from the University of Basel in 1984. He trained in neurology in Bern and Lausanne and performed research fellowships in experimental neurophysiology (Basel) and sleep (Ann Arbor, USA). In 2000 he was appointed professor of Neurology at the University of Zurich. In 2009 he founded the Neurocenter of Southern Switzerland. Since 2012 he is full professor at the University of Bern and director of the Neurology Department at Inselspital. Bassetti has been working thoughout his career mainly as a general neurologist with a special interest in clinical skills teaching. Using human and animal approaches he pioneered the studies between sleep, sleep disorders and stroke. He also made fundamental contributions to the etiology, pathophysiology and management of human narcolepsy. He authored over 560 publications (H index 105) and 10 books.

He served as president of the European Neurological Society, European Sleep Research Society and Swiss Neurological Society (SNS) and European Academy of Neurology (EAN). He has been the founder president of the Swiss Federation of Clinical Neurosocieties (SFCNS). For 8 years he served as board member of the Swiss Academy of Medical Sciences (SAMS). He currently serves as vice-president of the European Brain Council (EBC) and Dean of the Medical Faculty in Bern. He is honorary member of the SNS and EAN.





Mikele Epperly

Global Integrated Program Leader, Brain Health & Neurology Healthcare Ecosystems, Roche

Mikele Epperly is a Global Integrated Program Leader at Roche focusing on Brain Health & Women's Health. During her 25-year career, she has earned a reputation for building innovative functions and departments to address nebulous, future-forward topics.

While serving the healthcare-provider industry, Mikele oversaw Quality and Clinical Effectiveness including all clinical data collection, analysis, and initiatives to enhance patient safety, patient satisfaction, clinical outcomes, and value. She served in leadership and executive roles at Stanford Hospital and Scripps Health. Initiatives developed under her leadership exceeded \$100M+ in cost savings during the same time that quality metrics improved.

Within the biotechnology and pharmaceutical industry, Mikele collaborates with external stakeholders to shape a groundbreaking healthcare ecosystem for optimal access to care. Initiatives spearheaded by Mikele solve patients' pain points, enable timely diagnosis and treatment (ensuring optimal outcomes), and appear in multiple peer-reviewed journals.

Mikele has a PhD and MPH in Public Health from UCLA and a bachelor's degree in Human Biology from Stanford University. Mikele is also a fellow of the American College of Healthcare Executives and a Six Sigma Black Belt.













Tim Foxx

Director, Center for School Study Councils, University of Pennsylvania

As the director of the Center for School Study Councils (CSSC) at UPenn GSE, Tim Foxx works with school superintendents, boards, and district staff to help them keep pace with highly developed educational and management theory, research, and practice.

Mr. Foxx leads regional and national professional learning communities of public school leaders. He investigates strategies that system administrators can implement as they broaden their leadership in the midst of local and national uncertainty and polarization.

Mr. Foxx also designs and leads technical assistance projects with affiliated districts to build stronger, more productive relationships between districts, schools, and their communities. Those projects cover a broad range of topics from systemic transformation to community engagement to prioritization of wellness for all facets of K-12 ecosystems.

Mr. Foxx has worked with more than 100 educational, corporate, nonprofit, civic, philanthropic, and post-secondary institutions on a range of organizational development and improvement projects, strategic planning, equity, progressive pedagogy, and systems redesign. His work is focused on humanizing the most marginalized and being the voice for those who have historically been excluded from the public square.





Carmen Moreno

Chair, Child and Adolescent Neuropsychopharmacology Network, ECNP; Child and Adult Psychiatrist, Hospital Gregorio Marañón, Madrid, Spain

Carmen Moreno is a clinician, researcher and Associate Professor of Psychiatry (University Complutense of Madrid, Spain), and Head Section at the Institute of Psychiatry and Mental Health (Gregorio Marañón Hospital). Fort he past 15 years she has been focused on the neurobiological underpinnings of early phases of psychosis and other severe mental disorders and the development of specific interventions. She has participated in more tan 25 competitive research projects and has published more than 130 research papers. She has been Coordinator of the Childhood and Adolescence Programme at the Centre for Biomedical Research in Mental Health (CIBERSAM) between 2018 and 2023, and is currently Chair of the Child and Adolescent Neuropsychopharmacology Network of the European College of Neuropsychopharmacology (ECNP) and a member of the EmprEMA Network within the EMA".













Kevin Rostasy

President, European Paediatric Neurology Society (EPNS)

Professor Kevin Rostasy is the current President of the European Paediatric Neurology Society (EPNS) and has been Head of Paediatric Neurology at Witten/Herdecke University, Children's Hospital Datteln, in Germany since 2014. From 2007 to 2014 he was Head of Paediatric Neurology, Medical University Innsbruck, Austria, after spending 6 years as a Paediatric Neurologist at the Medical University, Göttingen, Germany where he gained his PhD in 2006. During his training he spent time working at the Hospital for Children, Boston, USA and the Royal Aberdeen Children's Hospital, Scotland.

His main field of clinical and research interested is neuroimmunology (MOGAD, MS, OMS, Autoimmune encephalitis, GBS/CIDP). An advocate for equitable access to the highest standard of patient care in neurology for children, he is involved in many collaborations including being Head of EPNS Research Group Neuroinflammatory Diseases and a longstanding a member of the German Society of Neuropediatrics (GNP).





Alexander Hudson

Senior Adviser, Democracy Assessment Unit, International IDEA

Dr Alexander Hudson is a Senior Adviser in the Democracy Assessment Unit of International IDEA's Global Programmes in Stockholm. As part of the team that produces the Global State of Democracy Indices and Global State of Democracy report, Hudson leads data collection, analysis and visualization work.

Prior to joining International IDEA in 2021, Hudson was a researcher at the Max Planck Institute for the Study of Religious and Ethnic Diversity in Göttingen, Germany. He has also worked for the University of Texas at Austin, the Comparative Constitutions Project, and the Centre for International Governance Innovation, and taught at the undergraduate level in Brazil, Canada, Germany, and the United States of America. He holds a PhD in political science from the University of Texas at Austin.

His research has been published by Cambridge University Press, and by journals including Comparative Politics, Democratization, Electoral Studies, and Political Research Quarterly.













Dennis Pamlin

Executive Director, The Net-Zero Compatibility Initiative, Mission Innovation

Dennis Pamlin is an entrepreneur and founder of 21st Century Frontiers. His background is in engineering, industrial economy and marketing.

Pamlin is a senior advisor at RISE, senior associate at Chinese Academy of Social Sciences, visiting research fellow at the Research Center of Journalism and Social Development at Renmin university, advisor to Centre for Sustainable Development at Confederation of Indian Industries (CII), Advisor to the EIT Climate KIC, and is a founding partner of UNFCCC's "Global Innovation Hub" that launched at COP26.

Pamlin is currently the executive director of Mission Innovation Net-Zero Compatibility Initiative https://www.misolutionframework.net/





Paulo Fontoura

Global Head and SVP Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Roche

Paulo Fontoura is the Senior Vice President and Global Head of Neuroscience, Immunology, Ophthalmology, Cardiology, Metabolism, Rare and Infectious Diseases Clinical Development at Roche. He joined Roche in 2008 and became VP and Global Head of Neuroscience Translational Medicine in 2010. In 2015 he became head of Neuroscience and Rare Diseases in late-stage development, and in 2021 he moved to his current position where he manages one of the industry-leading pharmaceutical pipelines.

Dr. Fontoura received his MD and PhD from the New University of Lisbon, performed his neurology residency in Lisbon, and a postdoctoral fellowship at Stanford University. He is a Fulbright Fellow, and has received several awards throughout his career, including a European Charcot Foundation Young Investigator Award, Gulbenkian Investigator and Christopher Reeve Foundation Awards. Since being at Roche he has received the pRED STAR leadership award and the RMM Award of Excellence for his work on Autism. In 2022 he was elected as a Fellow of the American Academy of Neurology.













Maria Teresa Ferretti

Affiliated researcher, Center for Alzheimer Studies, Karolinska Institut; External teacher (Privat Dozent), Medical university of Vienna; Clinical Development Lead, Syntropic Medical

Maria Teresa, a neuroscientist, and science advocate, brings 15+ years of global experience in brain research, specializing in neuroimmune interactions and sex and gender differences. She holds a Master's in Pharmaceutical Chemistry from the University of Cagliari and a PhD in Pharmacology and Therapeutics from McGill University. As a postdoc and group leader she worked at the University of Zurich in the group of Prof. Nitsch, where aducanumab, the first FDA-approved disease-modifying treatment for Alzheimer's, was discovered.

In 2016, she co-founded the 'Women's Brain Project' (WBP) a non-profit exploring the impact of sex and gender on brain and mental health for precision medicine, where she served as Chief Scientific Officer. Her dedication to scientific communication is evident through keynote lectures, media appearances, TED-x talks, and two authored books for the lay public.

She is faculty member of the Certificate for Advanced Studies (CAS) in Gender Medicine at the University of Zurich, an affiliated researcher at the Center of Alzheimer Research (CAR) at Karolinska, and an External Teacher (Privat Dozent) at the Medical University in Vienna. As of January 2024, she is Clinical Development Lead at Syntropic Medical, a startup dedicated to create innovative solutions for mental health patients, in Vienna.





Quazi Haque

Chief Medical Officer, Elysium Healthcare & Global Mental Health & Brain Science CoP Lead, Ramsay Healthcare

As Co-founder, Chief Medical Officer and Executive Operational Director, Quazi has helped to launch and scale up Elysium to one of the largest and most clinically successful providers of mental health and neurological care in the UK. Quazi trained in medicine at King's College in London and also completed his LLM with distinction. Having initially trained to specialize in neurology, he was drawn toward psychiatry following influential placements at the Beth Israel Hospital, Harvard, and Maudsley Hospital and Institute of Psychiatry. Over the years he has held senior academic positions at the Institute of Psychiatry and currently the University of London. He is the current President/CEO of the International Association of Forensic Mental Health Services, a leading global academic health network supporting equitable and effective care delivery amongst the most marginalised populations suffering from mental health problems. He is an award-winning researcher and author.

Quazi chairs the Ramsay Healthcare Global Mental Health Community of Practice spearheading innovation in psychiatry and neurological care. Quazi has extensive experience of mentoring emerging digitally-enable ventures in the field and is committed to ensuring innovation in this sector is accessible, equitable and effective for all patients and their families.













Peter Falkai

Board Member, European Brain Council; Past President, European Psychiatric Association

Prof. Dr. Med. Peter Falkai has been working in the field of psychiatry for 30 years. His main research interest is focused on the neurobiology of psychotic disorders, namely schizophrenia. He holds the position of Chair of the Department of Psychiatry and Psychotherapy of the University of Munich and is currently President of the European Psychiatric Association.

Prof. Falkai has been leading multidisciplinary teams of researchers, allowing the use of techniques ranging from functional imaging to gene expression in human post-mortem-tissue. His clinical and research expertise focuses continuously on the neurobiological origins and pathomorphological aspects as well as on causal treatment options of psychotic disorders.



Craig Ritchie

CEO and Founder, Scottish Brain Sciences

Prof Craig Ritchie is Founder and CEO of Scottish Brain Sciences and the Honorary Professor of the Psychiatry of Ageing at the University of Edinburgh, having moved from his role as Senior Lecturer in the Centre for Mental Health at Imperial College London in October 2014. He completed his PhD at UCL through an MRC Health Services Research Fellowship and was appointed as Senior Lecturer in Old Age Psychiatry at Imperial College London in 2007. He has also served as R&D Director at West London Mental Health Trust from 2010-14 and Deputy Director of the London Northwest NIHR Clinical Research Network. In 2014 he was appointed as Chair in Psychiatry of Ageing at the University of Edinburgh. In 2015 he established the Centre for Dementia Prevention and that year took on the academic leadership role of the EPAD (European Prevention of Alzheimer's Dementia) Programme. Between 2017 and 2022 he was the elected Chair of the Scottish Dementia Research Consortium and in 2020 he founded and was the inaugural Director of Brain Health Scotland. He has published over 400 academic papers, conference abstracts and book chapters and secured approximately €100M of grant funding in his career to date.

He established Scottish Brain Sciences in summer 2022 to accelerate the development of both diagnostics and therapeutics for early-stage neurodegenerative disease and moved full time into the role of CEO of this company in January 2023.













Orla Galvin

Executive Director, European Federation of Neurological Associations

Dr. Orla Galvin came to patient advocacy with a PhD in Medicine and background in drug discovery and design in both academic and industry environments. Transitioning to advocacy work at the umbrella patient organisation Retina International, Orla led high impact, multi-stakeholder socioeconomic studies, patient preference studies, and accessibility studies across the globe assessing both rare and common conditions.

Orla is an internationally invited speaker to both research and clinical learned societies (for example EURORDIS, EU Retina, ERN-EYE), patient organisations, and industries on topics such as:

- Patient and public involvement in advocacy, research and policy,
- Research in advocacy and policy/evidence-based advocacy,
- · Education in advocacy,
- Generation of real-world data,
- · Patient reported outcomes, and
- · Health economics

She is currently Executive Director of the European Federation of Neurological Associations (EFNA).





Tina Hjortlund

Head of Global Public Affairs and DE&I Officer, Lundbeck

As the head of Global Public Affairs at Lundbeck, I have the responsibility of building a strong company reputation, influencing public policy, and finding common ground with stakeholders. As such adding value to patients, society and our future business.

In addition to my global public affairs role, I am also appointed Lundbeck's DE&I Officer and here lead our efforts in building an even more inclusive organization. Fields of expertise: Public affairs, communication, positioning, policy, public private partnerships, advocacy, stakeholder management, reputation building and DE&I.













William Hynes

Adjunct Professor at Rebuilding Macroeconomic, University College London; Adjunct Professor, Santa Fe Institute; Adjunct Professor, Johns Hopkins School for Advanced International Studies; World Bank economist

William Hynes is a Senior Advisor to the Secretary General and the Head of the New Approaches to Economic Challenges (NAEC) Unit which provides a space to question traditional economic ideas and offer new economic narratives, new tools, methods and policy approaches.

He previously worked as a Senior Economist at NAEC, Advisor in the Sherpa and Global Governance Unit, a policy analyst in the Development Co-operation Directorate and an economic affairs officer at the World Trade Organisation.

William is an Associate Fellow and Adjunct Professor in International Economics at the Johns Hopkins University School of Advanced International Studies, has a doctorate from Oxford University and was a Marie Curie Fellow at the London School of Economics.





Paweł Świeboda

Paweł Świeboda, Founder, Neurocentury

Paweł Świeboda is Founder of NeuroCentury, a brain health policy hub as well as Practice Lead Neurotechnology at the International Centre for Future Generations, Senior Visiting Fellow at the European Policy Centre and Senior Advisor for Brain Health at FIPRA. He is Member of the Steering Committee of the Brain Capital Alliance and Member of the Board of Advisor of the Euro-Mediterranean Economists' Association. In his previous role, he was Director General of the Human Brain Project and CEO of EBRAINS AISBL. In this capacity, he oversaw the building of the Research Infrastructure for the study of the brain - EBRAINS. In the earlier period, he was Deputy Head and Head of Research of the European Political Strategy Centre at the European Commission. He is a member of the European Commission's Expert Group on the Economic and Societal Impact of Research and Innovation. He had served on the Global Agenda Council on Europe of the World Economic Forum. He is an advisor to European and global companies and policy organisations. Paweł hosts the NeuroCentury podcast on key trends in brain health, mental health, neurotechnology, brain capital and ethics.













Marco Mohwinckel

Mental health and health technology investor and advisor

Marco Mohwinckel has been Global Head Integrated Care Solutions at Janssen Healthcare Innovation (JHI) since 2011. Prior to taking on this role, Mohwinckel headed the Neuroscience Business Unit and was a member of the Management Committee of Janssen (Pharmaceutical Companies of Johnson & Johnson) in the UK, where he launched new partnership working models with the NHS. Before joining Janssen in 2007, Mohwinckel was principal at the global strategy consulting firm Monitor Group (now Monitor Deloitte), where he advised clients in the life science sector on strategic and operational issues across Europe and the US. He serves on the International Advisory Panel for the European Connected Health Alliance, the Advisory Board of the Digital Health Forum and Health XL, and has been acting as mentor to several digital health startups. He is co-author of Beyond magic bullets: true innovation in health care (Nature Reviews, Drug Discovery, Vol.13 Feb 2013). Mohwinckel holds a degree in Economics and Business Administration from Bocconi University in Milan, Italy.





Marcel Tanner

President, Swiss Academies of Arts & Sciences

Prof Marcel Tanner is President of the Swiss Academy of Arts and Sciences and a board member of Fondation Botnar. He is Director Emeritus of the Swiss Tropical and Public Health Institute (Swiss TPH) and also a Professor Emeritus of Epidemiology and Medical Parasitology at the University of Basel. His research interests include the fields of global health, epidemiology, health systems, infectious diseases and public health. Over the course of his research career, he has lived and worked extensively in Africa and Asia. He headed the Tropical Institute in Ifakara, Tanzania, which eventually grew into the Ifakara Health Institute. Among his notable work, Prof Tanner was instrumental in the development of malaria vaccines. He also implemented large programmes in the field of health planning and the training of health workers on behalf of the Swiss and Tanzanian governments. He is the author of over 700 publications, 51 book chapters and numerous reports for governments and international organizations. He obtained his PhD in medical biology from the University of Basel and a master's in public health from the University of London, UK.





Henrik Peersen

Secretary General, Hjernerådet (Norwegian Brain Council)

Henrik Peersen is general secretary in the Norwegian Brain Council. He has previously been member of the council board for several years and acted as chairman in 2017-2019 when the first Norwegian brain health strategy was decided. Peersen has been representing patient organisations as general secretary the last decade and has educational background from sociology and conflict management.













Azad Bonni

SVP Roche pRED Global Head of Neuroscience & Rare Diseases, Roche

Azad serves in an executive leadership role at Roche as Senior Vice President and Global Head of Neuroscience and Rare Diseases in pRED. He oversees a rich and differentiated portfolio from research to completion of Phase 2 trials. Before Roche, Azad was Head of Neuroscience at Washington University in St Louis, and prior to that Professor of Neurobiology at Harvard. Azad is an international leader in neuroscience who has made fundamental discoveries on mechanisms of neuronal connectivity in the brain. He received his MD at Queen's University, neurology residency at McGill University, and PhD and postdoctoral training at Harvard University. Azad has trained over 40 exceptional graduate students and postdoctoral fellows, many of whom have launched their own independent laboratories at prestigious institutions. He has received numerous honors and awards including election to the American Association for the Advancement of Science, Royal Society of Canada, and National Academy of Medicine.





Kana Enomoto

Director of Brain Health, McKinsey Health Institute

Kana Enomoto is a global thought leader and accomplished executive with a strong record of achieving public-policy goals, delivering programmatic impact, and inspiring organizational and social change.

As a partner at McKinsey and the Director of Brain Health for the McKinsey Health Institute, Kana works with cross-sector stakeholders, including government entities, payers, providers, investors, employers, and not-for-profit organizations to better serve people with, or at risk for, mental and substance-use disorders.

Prior to joining McKinsey, Kana was acting administrator for the US Substance Abuse and Mental Health Services Administration, where she provided executive direction and national policy leadership. She also served as senior advisor to the US Surgeon General, where she provided strategic guidance on efforts to combat the opioid epidemic.













Rym Ayadi

Adjunct Professor of Banking, Finance and Economics, Bayes Business School at City University London; Founder and President of the Euro-Mediterranean Economists Association (EMEA)

Professor Rym Ayadi is Founder and President of the Euro-Mediterranean Economists Association (EMEA), a Barcelona based regional Think Tank that serves as a leading independent and innovative policy research institution. Co-Founder of the Brain Capital Alliance, and founder and Director of the Euro-Mediterranean and African Network for Economic Studies (EMANES), Professor at the Bayes Business School (Former CASS) of the City University of London and Senior Advisor at the Centre for European Policy Studies (CEPS). She is the Chair of the European Banking Authority (EBA) Banking Stakeholders Group (BSG) of which she acted as elected Chair from February 2019 to present. Professor Ayadi is an Economist and international academic expert on international business and financial systems, financial markets and institutions, global financial regulation and governance, and socio-economic development and foresight in economies in transition. She is currently Member in several international high-level Academic, Advisory Committees and Editing Boards. For more information visit www.rymayadi.com





Ekkehard Ernst

President, Geneva Macro Labs

Ekkehard Ernst is Chief Macro-economist at the International Labour Organization where he signs responsible for flagship reports on global labour market developments such as ILO's World Employment and Social Outlook Trends report. He publishes regularly on the implications of artificial intelligence, demographic change and globalization for the future of work, including in developing countries, as well as on the transition to a sustainable society. In 2017, Ekkehard co-founded Geneva Macro Labs, a platform to identify, develop and implement solutions to address global challenges. Together with his team he brings together international thought leaders and practitioners to promote and advance the United Nations Sustainable Development Agenda. He currently develops and implements new solutions to value natural capital, notably ocean assets to support a Just Transition. Ekkehard has international experience at the OECD and the European Central Bank. He is member of various advisory boards, including the European Parliament's International Advisory Board of the Science and Technology Committee, the UK's Productivity Insight Network, Pillars, CEPS, The Conference Board, and the Economists Network of the German Ministry of Collaboration and Development. He holds a PhD from the Ecole des Hautes Etudes en Sciences Sociales (Paris).













Shiva Dustdar

Head, European Investment Bank Institute

Shiva Dustdar currently serves as the Head and Director of the EIB Institute, which brings the values and mission of the EIB Group close to society through philanthropic, academic, social and cultural activities supporting its climate, innovation and development priorities. Shiva has 30 years of experience in the financial industry working for large private and public institutions in New York, London and Luxembourg. Since joining EIB in 2003, she has worked in risk management, lending, investing and advising in innovative companies.

Shiva started her career in 1993 at J.P. Morgan in Investment Banking in New York before joining Fitch Rating Agency in 1999 to set up its European High Yield rating business. She holds a BA (Magna cum Laude) in Economics from Columbia University in New York and an Executive MBA from London Business School (LBS). Shiva is an innovation finance expert and regular speaker on innovation and impact financing, gender smart investing, digital and green financing and actively engaged in networks that promote sustainable and mission-oriented financing. In 2023 received the WIN-Women International Global Inspiring Women Worldwide Award for being an "authentic, courageous feminine leader in the global stage".





Alex Struc
CEO, Goalsfirst

Alex Struc is the founder and CEO of Goalsfirst - a UK-based alternative investment firm founded to enable equitable ownership of impact (or influence) and access to superior financial returns through an integrated multidisciplinary investment approach and strategic engagement with investees. Before Goalsfirst, Mr. Struc spent 15 years managing credit assets at PIMCO, including firmwide exposure to banks and insurance and, in his earlier years, leveraged loans and collateralized loan obligations portfolios. Mr. Struc led the industry-wide efforts on engagement as the Chair of the inaugural PRI Bondholder Engagement Committee in 2017, founded PIMCO's first dedicated ESG investment platform, and structured first-of-their-kind liquid bonds linked to the U.N. Sustainable Development Goals.













Nathalie Hilmi

Head of Environmental Economics, Center for Science, Monaco

Dr Nathalie Hilmi is an expert in Macroeconomics and International Finance. In 2010, she joined the Centre Scientifique de Monaco as head of the section « environmental economics » and collaborated with IAEA's Environment Laboratories to initiate correlation studies between environmental sciences and economics to better evaluate the socioeconomic extent of impacts and costs of action versus inaction with regard to carbon emissions. She is lead author for IPCC Special Report on the Ocean and Cryosphere in a Changing Climate (SROCC) and IPCC main report AR6. She is also lead author for MAR1, the first Mediterranean Assessment report by MedECC, which co-won the 2020 North-South Prize of the Council of Europe.





George Vradenburg

Chairman, Davos Alzheimer's Collaborative

George Vradenburg is the Chairman of the Board of the Davos Alzheimer's Collaborative, a global public-private-patient foundation focused on linking and scaling Alzheimer's and Brain Health research and delivery systems around the world. DAC was launched in Davos in 2021 by the Global CEO Initiative on Alzheimer's Disease (CEOi) and the World Economic Forum. George is also the Chairman and Co-Founder of UsAgainstAlzheimer's (UsA2), a U.S.-based venture philanthropy and advocacy organization committed to increasing the scale and speed of therapeutic and risk mitigation initiatives to prevent Alzheimer's.





Michael Oberreiter

Head of Global Access, Roche

Michael Oberreiter is Head of Global Access at Roche. He is an economist by training and completed a post-graduate diploma and master studies in International Politics and Communications. Michael has been involved in the field of health policy, patient access, capacity building and health economics for over 25 years. His experience spans across different therapeutic areas and countries – including Austria, Germany, Hungary, Asia Pacific (APAC) and at a global level. Michael is a member of the board of All. Can International, an international multi-stakeholder not-for-profit organisation working to improve the efficiency of cancer care by focusing on what matters to patients.









